Review will assess risk of leukoencephalopathy, a condition affecting the brainEMA’s safety committee (PRAC) has started a review of medicines containing levamisole, authorised in…, Agenda Agenda of the PRAC meeting 1-4 September 2025DraftReference Number: EMA/PRAC/234907/2025 English (EN…, PRAC statistics: September 2025 , PRAC statistics: September 2025 English (EN) (33.17 M
EMA - European Medicines Agency · September 05, 2025
PRAC meeting highlights, 1–4 September 2025
Original title: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1 – 4 September 2025
Published by EMA - European Medicines Agency. HealthSignal links to the original document; the summary above is extracted from the source text.